Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers

NCT01825603 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT01825603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01825603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Lead sponsor
University of Nebraska
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2013
Completion date
June 1, 2017
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ampulla of vater adenocarcinoma, gallbladder adenocarcinoma, metastatic pancreatic adenocarcinoma, pancreatic adenocarcinoma, stage iii ampulla of vater cancer, stage iii intrahepatic cholangiocarcinoma, stage iii pancreatic cancer, stage iiia gallbladder cancer, stage iiia hilar cholangiocarcinoma, stage iiib gallbladder cancer, stage iiib hilar cholangiocarcinoma, stage iv ampulla of vater cancer, stage iva gallbladder cancer, stage iva hilar cholangiocarcinoma, stage iva intrahepatic cholangiocarcinoma, stage iva pancreatic cancer, stage ivb gallbladder cancer, stage ivb hilar cholangiocarcinoma, stage ivb intrahepatic cholangiocarcinoma, stage ivb pancreatic cancer